| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response.
|
Lancet
|
2009
|
6.96
|
|
2
|
Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment.
|
Lancet
|
2006
|
5.98
|
|
3
|
Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa.
|
AIDS
|
2008
|
5.26
|
|
4
|
Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies.
|
PLoS Med
|
2011
|
4.29
|
|
5
|
Comparison of two active case-finding strategies for community-based diagnosis of symptomatic smear-positive tuberculosis and control of infectious tuberculosis in Harare, Zimbabwe (DETECTB): a cluster-randomised trial.
|
Lancet
|
2010
|
3.58
|
|
6
|
Achieving the health Millennium Development Goals for South Africa: challenges and priorities.
|
Lancet
|
2009
|
3.35
|
|
7
|
Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners.
|
Am J Respir Crit Care Med
|
2004
|
3.26
|
|
8
|
Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B.
|
AIDS
|
2007
|
3.19
|
|
9
|
Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus.
|
Clin Infect Dis
|
2002
|
2.60
|
|
10
|
Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme.
|
AIDS
|
2010
|
2.60
|
|
11
|
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.
|
N Engl J Med
|
2014
|
2.42
|
|
12
|
Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources.
|
Lancet Infect Dis
|
2010
|
2.38
|
|
13
|
Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program.
|
Clin Infect Dis
|
2008
|
2.32
|
|
14
|
Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa.
|
Clin Infect Dis
|
2009
|
2.25
|
|
15
|
Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study.
|
JAMA
|
2005
|
2.15
|
|
16
|
Use of traditional medicine by HIV-infected individuals in South Africa in the era of antiretroviral therapy.
|
Psychol Health Med
|
2007
|
2.08
|
|
17
|
HIV infection does not affect active case finding of tuberculosis in South African gold miners.
|
Am J Respir Crit Care Med
|
2009
|
2.07
|
|
18
|
Provider-initiated symptom screening for tuberculosis in Zimbabwe: diagnostic value and the effect of HIV status.
|
Bull World Health Organ
|
2010
|
2.03
|
|
19
|
"That is why I stopped the ART": patients' & providers' perspectives on barriers to and enablers of HIV treatment adherence in a South African workplace programme.
|
BMC Public Health
|
2008
|
1.96
|
|
20
|
Performance characteristics of the Cepheid Xpert MTB/RIF test in a tuberculosis prevalence survey.
|
PLoS One
|
2012
|
1.53
|
|
21
|
Evaluation of a workplace HIV treatment programme in South Africa.
|
AIDS
|
2007
|
1.52
|
|
22
|
Barriers to implementation of isoniazid preventive therapy in HIV clinics: a qualitative study.
|
AIDS
|
2010
|
1.50
|
|
23
|
Diagnostic accuracy of a urine lipoarabinomannan enzyme-linked immunosorbent assay for screening ambulatory HIV-infected persons for tuberculosis.
|
J Acquir Immune Defic Syndr
|
2011
|
1.41
|
|
24
|
Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: a cohort study.
|
BMC Infect Dis
|
2008
|
1.41
|
|
25
|
Undiagnosed tuberculosis among HIV clinic attendees: association with antiretroviral therapy and implications for intensified case finding, isoniazid preventive therapy, and infection control.
|
J Acquir Immune Defic Syndr
|
2012
|
1.39
|
|
26
|
Stable incidence rates of tuberculosis (TB) among human immunodeficiency virus (HIV)-negative South African gold miners during a decade of epidemic HIV-associated TB.
|
J Infect Dis
|
2003
|
1.36
|
|
27
|
Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events.
|
AIDS
|
2008
|
1.32
|
|
28
|
Low haemoglobin predicts early mortality among adults starting antiretroviral therapy in an HIV care programme in South Africa: a cohort study.
|
BMC Public Health
|
2010
|
1.30
|
|
29
|
Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study.
|
PLoS One
|
2013
|
1.29
|
|
30
|
Why have trials of isoniazid preventive therapy among people with HIV infection not demonstrated an effect on mortality?: did close examination of the trees obscure our view of the wood?
|
AIDS
|
2010
|
1.22
|
|
31
|
Changing predictors of mortality over time from cART start: implications for care.
|
J Acquir Immune Defic Syndr
|
2011
|
1.22
|
|
32
|
Mortality associated with delays between clinic entry and ART initiation in resource-limited settings: results of a transition-state model.
|
J Acquir Immune Defic Syndr
|
2013
|
1.18
|
|
33
|
Tuberculosis and HIV coinfection: current state of knowledge and research priorities.
|
J Infect Dis
|
2007
|
1.18
|
|
34
|
Does tuberculosis increase HIV load?
|
J Infect Dis
|
2004
|
1.18
|
|
35
|
Thibela TB: design and methods of a cluster randomised trial of the effect of community-wide isoniazid preventive therapy on tuberculosis amongst gold miners in South Africa.
|
Contemp Clin Trials
|
2010
|
1.16
|
|
36
|
Adverse events with isoniazid preventive therapy: experience from a large trial.
|
AIDS
|
2010
|
1.15
|
|
37
|
Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting.
|
AIDS
|
2010
|
1.11
|
|
38
|
Genotype MTBDRplus for direct detection of Mycobacterium tuberculosis and drug resistance in strains from gold miners in South Africa.
|
J Clin Microbiol
|
2012
|
1.09
|
|
39
|
Incidence of tuberculosis and HIV and progression of silicosis and lung function impairment among former Basotho gold miners.
|
Am J Ind Med
|
2009
|
1.09
|
|
40
|
A novel HIV treatment model using private practitioners in South Africa.
|
Sex Transm Infect
|
2012
|
1.05
|
|
41
|
The burden of silicosis, pulmonary tuberculosis and COPD among former Basotho goldminers.
|
Am J Ind Med
|
2008
|
1.05
|
|
42
|
Contrasting predictors of poor antiretroviral therapy outcomes in two South African HIV programmes: a cohort study.
|
BMC Public Health
|
2010
|
1.04
|
|
43
|
Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa.
|
AIDS
|
2010
|
1.03
|
|
44
|
Contrasting reasons for discontinuation of antiretroviral therapy in workplace and public-sector HIV programs in South Africa.
|
AIDS Patient Care STDS
|
2011
|
0.99
|
|
45
|
Tuberculosis control in South African gold mines: mathematical modeling of a trial of community-wide isoniazid preventive therapy.
|
Am J Epidemiol
|
2015
|
0.98
|
|
46
|
Cytomegalovirus viremia as a risk factor for mortality prior to antiretroviral therapy among HIV-infected gold miners in South Africa.
|
PLoS One
|
2011
|
0.97
|
|
47
|
Applying ethical principles to international community-based research: a case study from the Consortium to Respond Effectively to the AIDS-TB Epidemic (CREATE) .
|
IRB
|
2014
|
0.92
|
|
48
|
Recurrent tuberculosis: relapse, reinfection, and HIV.
|
J Infect Dis
|
2010
|
0.90
|
|
49
|
Polymorphisms in the tumor necrosis factor-alpha gene promoter may predispose to severe silicosis in black South African miners.
|
Am J Respir Crit Care Med
|
2002
|
0.88
|
|
50
|
Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa.
|
Antivir Ther
|
2013
|
0.87
|
|
51
|
HIV suppression with stavudine 30 mg versus 40 mg in adults over 60 kg on antiretroviral therapy in South Africa.
|
AIDS
|
2009
|
0.87
|
|
52
|
Pregnancy incidence and correlates during the HVTN 503 Phambili HIV vaccine trial conducted among South African women.
|
PLoS One
|
2012
|
0.86
|
|
53
|
"Proof-of-concept" evaluation of an automated sputum smear microscopy system for tuberculosis diagnosis.
|
PLoS One
|
2012
|
0.85
|
|
54
|
Opportunities afforded by new drugs for tuberculosis.
|
Lancet Infect Dis
|
2010
|
0.83
|
|
55
|
HIV infection and chronic chest disease as risk factors for bacterial pneumonia: a case-control study.
|
AIDS
|
2003
|
0.81
|
|
56
|
A trial of mass isoniazid preventive therapy for tuberculosis control.
|
N Engl J Med
|
2014
|
0.80
|
|
57
|
The HVTN503/Phambili HIV vaccine trial: a comparison of younger and older participants.
|
Int J STD AIDS
|
2013
|
0.79
|
|
58
|
Molecular epidemiology of Mycobacterium tuberculosis among South African gold miners.
|
Ann Am Thorac Soc
|
2015
|
0.78
|
|
59
|
Durable HIV RNA resuppression after virologic failure while remaining on a first-line regimen: a cohort study.
|
Trop Med Int Health
|
2014
|
0.78
|
|
60
|
Eligibility for isoniazid preventive therapy in South African gold mines.
|
PLoS One
|
2013
|
0.77
|
|
61
|
Attitudes to directly observed antiretroviral treatment in a workplace HIV care programme in South Africa.
|
Sex Transm Infect
|
2007
|
0.75
|
|
62
|
Clinic-level factors influencing patient outcomes on antiretroviral therapy in primary health clinics in South Africa.
|
AIDS
|
2016
|
0.75
|
|
63
|
Business and AIDS: sectoral challenges and opportunities.
|
AIDS
|
2007
|
0.75
|
|
64
|
Brief Report: The Effect of Antiretroviral Therapy and CD4 Count on Markers of Infectiousness in HIV-Associated Tuberculosis.
|
J Acquir Immune Defic Syndr
|
2015
|
0.75
|
|
65
|
Strategies to Accelerate HIV Care and Antiretroviral Therapy Initiation Following HIV Diagnosis: a Randomized Trial.
|
J Acquir Immune Defic Syndr
|
2017
|
0.75
|